SCHEMBL438813

SCHEMBL438813

CC(C)(C)OC(=O)Nc1cc(-c2ccnc(Cl)c2)cs1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.55
ROCK1 Q13464 5/20 0.55
PRKACA P17612 3/20 0.55
ATR Q13535 1/20 0.45
AAK1 Q2M2I8 1/20 0.44
SREBF2 Q12772 1/20 0.41
ROCK2 O75116 1/20 0.41
CYP17A1 P05093 1/20 0.40
RORC P51449 3/20 0.39
RORB Q92753 2/20 0.39
ABL1 P00519 1/20 0.39
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
METAP1 P53582 1/20 0.38
MAP4K4 O95819 1/20 0.38
CNR1 P21554 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28997311 0.84 ROCK1 (0.41) CYP3A4ROCK1PRKACAATRAAK1
SCHEMBL23554099 0.82 RORC (0.54) CYP3A4ROCK1PRKACACYP17A1RORC
SCHEMBL12788367 0.81 CYP17A1 (0.57) ATRAAK1SREBF2CYP17A1SMARCA2
SCHEMBL448401 0.78 CYP3A4 (0.57) CYP3A4ROCK1AAK1SREBF2ABL1
SCHEMBL28834313 0.77 GAA (0.39) ATRCYP17A1METAP1
SCHEMBL19513016 0.77 ATR (0.44) ATRAAK1SREBF2CYP17A1SMARCA2
SCHEMBL8242390 0.76 METAP1 (0.39) CYP3A4ROCK1PRKACAATRSREBF2
SCHEMBL12385389 0.76 AKT1 (0.39) SREBF2CYP17A1ABL1METAP1
SCHEMBL1501665 0.76 SMARCA2 (0.57) ATRCYP17A1SMARCA2SMARCA4MAP4K4
SCHEMBL1352029 0.72 RAF1 (0.48) CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278306-B2 C-met protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-02 US disclosed
US-20120065213-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 US disclosed
US-8058271-B2 Selective inhibitors of rock protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-15 US disclosed
US-20070270386-A1 Selective inhibitors of rock protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270386-A1 Selective inhibitors of rock protein kinase and uses thereof ROCK1, ROCK2, MYLK CYP3A4 4395/4885ROCK1 1/4885PRKACA 99/4885
US-20120065213-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, MYLK CYP3A4 3859/4885ROCK1 4/4885PRKACA 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.